Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide (Q33418389)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Karthik Ramasamy

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

2

object named as

Dean Smith

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

7

object named as

Kwee Yong

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Robin Aitchison

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Norbert Blesing

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Pamela Roberts

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Andrew Peniket

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Neil Rabin

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

28 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

94

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

643-649

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Pathogenesis and treatment of renal failure in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Bendamustine in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2238-2

21 January 2018

Identifiers

10.1007/S00277-014-2238-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25345871%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33418389&oldid=1789694011"